Indapamid Laropharm

Indapamide, the active ingredient in Indapamid Laropharm, is a thiazide‑like diuretic presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to reduce fluid retention in adults with hypertension or edema secondary to congestive heart failure.

GNH USA supplies Indapamid Laropharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution across multiple regulatory markets and diverse therapeutic areas.

Indapamide is a thiazide‑like diuretic that acts on the renal distal convoluted tubule to manage conditions related to fluid overload and elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in patients with primary or essential hypertension. - Edema associated with congestive heart failure: promotes fluid excretion to reduce peripheral and pulmonary swelling. - Primary hypertension: assists in long‑term blood pressure control to lower cardiovascular risk. - Fluid overload in chronic heart failure: helps maintain euvolemia and improve symptom burden.

Indapamide may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Increased urinary frequency or volume. - Headache, often mild and transient. - Electrolyte disturbances such as mild hypokalemia. - Nausea or mild gastrointestinal upset. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance (e.g., marked hyponatremia, hypokalemia). - Allergic reactions including rash, pruritus, or angio‑edema. - Acute gout attacks due to uric acid elevation. - Pancreatitis, presenting with abdominal pain and elevated enzymes. - Blood dyscrasias such as leukopenia or thrombocytopenia. - Renal impairment worsening, particularly in patients with pre‑existing kidney disease.

Before initiating therapy with Indapamide, clinicians should assess patient‑specific risk factors and monitor relevant clinical parameters.

- Electrolyte monitoring: check serum potassium and sodium regularly, especially in the first weeks. - Renal function: evaluate creatinine clearance before starting and during treatment. - Diabetes mellitus: monitor blood glucose as diuretics may affect glycemic control. - Hepatic impairment: use with caution in patients with severe liver disease. - Elderly patients: consider lower starting doses due to increased sensitivity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Indapamide can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Lithium: concurrent use may increase lithium levels, risking toxicity. - Cyclosporine: combined therapy can exacerbate nephrotoxicity. - High‑dose NSAIDs: may reduce diuretic effectiveness and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive potassium‑sparing effect may cause hyperkalaemia. - Digoxin: enhanced serum digoxin concentrations can increase risk of arrhythmia. - Beta‑blockers: combined use may lead to excessive hypotension. - Sulfonylurea antidiabetics: diuretic‑induced hypoglycaemia may require dose adjustment.